The ENGOT-ov50/INNOVATE-3 trial is intended for patients who have recently been diagnosed with ovarian cancer that progressed and became resistant to chemotherapy containing platinum (platinum resistant ovarian cancer). This clinical trial is evaluating the safety and efficacy of the NovoTTF-100L(O) System for use in platinum resistant ovarian cancer, when added to paclitaxel which is normally given to patients in this condition. The NovoTTF-100L(O) System delivers Tumor Treating Fields (TTFields) to the cancer in the abdomen. Novocure Ltd., the trial sponsor, maintains this website to help patients get basic information about this clinical trial and facilitate their accessibility to medical centers that offer participation in this trial. If you would like to take part in the INNOVATE-3 trial, please contact one of the participating centers as soon as possible. If you have questions concerning your medical condition and recommended treatment, please consult with your treating doctor.